Aprogen Biologics Inc. (KRX:003060)
South Korea · Delayed Price · Currency is KRW 236.00
+1.00 (0.43%)
At close: Apr 8, 2026
Aprogen Biologics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -170,331 | -104,979 | -118,270 | 12,639 | 8,103 |
Depreciation & Amortization | 19,185 | 19,090 | 21,398 | 2,404 | 2,072 |
Loss (Gain) From Sale of Assets | -88.69 | -16.15 | 151,537 | -3.1 | -53.08 |
Asset Writedown & Restructuring Costs | 637.76 | 154.08 | 2,271 | 264.15 | 2,134 |
Loss (Gain) From Sale of Investments | 9,616 | 9,934 | -34,724 | -1,380 | -1,623 |
Loss (Gain) on Equity Investments | 77,377 | 29,047 | -75,012 | -1,353 | -352.2 |
Provision & Write-off of Bad Debts | -0.49 | 0.01 | -24.29 | -2,224 | -26.23 |
Other Operating Activities | 28,250 | 16,980 | 31,164 | 1,476 | -720.21 |
Change in Accounts Receivable | 3,021 | -2,217 | 1,218 | -637.92 | -494.75 |
Change in Inventory | -149.22 | -5,708 | -3,284 | -1,180 | -1,023 |
Change in Accounts Payable | -613.74 | 662.83 | -2,373 | 313.46 | -155.63 |
Change in Other Net Operating Assets | -5,136 | 6,056 | -7,550 | 15,410 | -14,088 |
Operating Cash Flow | -38,233 | -30,996 | -33,651 | 25,728 | -6,227 |
Capital Expenditures | -9,625 | -15,264 | -28,088 | -1,284 | -796.19 |
Sale of Property, Plant & Equipment | 210.7 | 16.53 | 16.82 | 16.36 | 66.71 |
Cash Acquisitions | -5,080 | - | -9,223 | - | - |
Divestitures | 2,622 | 200 | - | 3,074 | - |
Sale (Purchase) of Intangibles | -154.86 | -187.34 | -308.06 | -261.4 | -145.94 |
Investment in Securities | -880.82 | -12,262 | -79,690 | 22,197 | 75,048 |
Other Investing Activities | -72,212 | -24,225 | 22,086 | -76,742 | -97,329 |
Investing Cash Flow | -85,119 | -51,722 | -95,206 | -53,001 | -23,156 |
Short-Term Debt Issued | 41,800 | 53,950 | 49,610 | 20,500 | - |
Long-Term Debt Issued | 97,972 | 39,997 | 114,611 | - | - |
Total Debt Issued | 139,772 | 93,947 | 164,221 | 20,500 | - |
Short-Term Debt Repaid | -3,000 | -60,650 | -122,110 | -4,000 | - |
Long-Term Debt Repaid | -1,635 | -61,594 | -353.06 | -262.55 | -349.3 |
Total Debt Repaid | -4,635 | -122,244 | -122,463 | -4,263 | -349.3 |
Net Debt Issued (Repaid) | 135,136 | -28,297 | 41,758 | 16,237 | -349.3 |
Issuance of Common Stock | 0.61 | 115,759 | 40,000 | 0.24 | - |
Repurchase of Common Stock | - | -21.72 | -4,425 | - | - |
Other Financing Activities | -0.08 | -2,468 | 37,957 | -455.34 | -0.96 |
Financing Cash Flow | 135,137 | 84,972 | 115,289 | 15,782 | -350.26 |
Foreign Exchange Rate Adjustments | 301.4 | - | 11.65 | 25.04 | 11.02 |
Miscellaneous Cash Flow Adjustments | - | - | - | 0 | -0 |
Net Cash Flow | 12,086 | 2,253 | -13,555 | -11,465 | -29,722 |
Free Cash Flow | -47,857 | -46,261 | -61,739 | 24,444 | -7,023 |
Free Cash Flow Margin | -65.36% | -68.66% | -70.67% | 37.50% | -12.43% |
Free Cash Flow Per Share | -242.19 | -367.96 | -978.68 | 604.74 | -176.20 |
Cash Interest Paid | 4,930 | 2,213 | 151.04 | 25.77 | 89.51 |
Cash Income Tax Paid | 1,736 | -31.26 | -2,485 | 2,115 | 1,810 |
Levered Free Cash Flow | -82,778 | -24,026 | 13,979 | 104,474 | -97,245 |
Unlevered Free Cash Flow | -76,091 | -20,579 | 16,272 | 104,645 | -97,226 |
Change in Working Capital | -2,878 | -1,207 | -11,990 | 13,906 | -15,761 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.